All Data
Transforming Drug Development with Science & Innovation.
Lead Product(s): GP1681
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: CytoAgents
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
Partnership will focus on utilizing Quotient’s integrated service portfolio to support the rapid development of CytoAgents’ lead COVID-19 drug candidate, GP1681, for Phase I and II in 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SDC-1801
Therapeutic Area: Infections and Infectious Diseases Product Name: SDC-1801
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: UKRI
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding December 03, 2020
Details:
Sareum’s received £174,000 in grant funding to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe-phase Covid-19.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: UK Government
Deal Size: $9.0 million Upfront Cash: $13.1 million
Deal Type: Agreement October 20, 2020
Details:
The UK government has signed a contract to develop a COVID-19 human challenge study model, which would be the first of its kind in the world if it goes ahead.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PolyPEPI-SCoV-2 peptide vaccine,Montanide ISA 51VG
Therapeutic Area: Infections and Infectious Diseases Product Name: PolyPEPI-SCoV-2 peptide
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
PolyPEPI-SCoV-2 vaccine administered with Montanide ISA 51VG adjuvant was safe in two mouse models and elicited highly specific, TH1-biased CD8+ and CD4+ T cell responses against all four structural proteins of the virus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IFN Alpha-14
Therapeutic Area: Infections and Infectious Diseases Product Name: Alfacyte
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
ILC Therapeutics' unique synthetic Interferon called Alfacyte™ is fifteen to twenty times more effective at preventing the spread of SARS-CoV-2 in cell culture than other commercially-available Interferons such as Interferon alpha 2 and Interferon beta 1a.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SARS-CoV2 neutralizing antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: FairJourney Biologics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The newly-identified panel of antibodies have been shown to block infection at doses as low as 20pM in pseudoviral assays and 100pM in live coronavirus assays, surpassing or matching the best antibodies reported.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SPOR-COV
Therapeutic Area: Infections and Infectious Diseases Product Name: SPOR-COV
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: SporeGen
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2020
Details:
Under the agreement, the parties will share any costs and commercial returns from SPOR-COV and plan to complete a pre-clinical programme with the aim of being ready to enter the first human clinical trials within 18 months.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Covid 19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Innovate UK
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
The funding will be used to initiate a Phase 1 clinical trial (“COVIDITY”) during 2021. Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T cells that identify and destroy diseased cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: UK Research and Innovation
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
With the grant proceeds, Vaccitech will complete preclinical studies and manufacture sufficient quantities required to initiate a Phase 1 clinical study of its new COVID-19 vaccine candidate in 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TZLS-501
Therapeutic Area: Infections and Infectious Diseases Product Name: TZLS-501
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
United States Patent and Trademark Office has granted a patent for methods and use of fully human monoclonal antibody that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
